Galectin-3 reflects mitral annular plane systolic excursion being assessed by cardiovascular magnetic resonance imaging

• Verfasst von: Kim, Seung‑Hyun [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Verfasst von: Natale, Michèle [VerfasserIn]
• Verfasst von: Hoffmann, Julia [VerfasserIn]
• Verfasst von: Reckord, Nadine [VerfasserIn]
• Verfasst von: Hoffmann, Ursula [VerfasserIn]
• Verfasst von: Budjan, Johannes [VerfasserIn]
• Verfasst von: Henzler, Thomas [VerfasserIn]
• Verfasst von: Papavassiliu, Theano [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Galectin-3 reflects mitral annular plane systolic excursion being assessed by cardiovascular magnetic resonance imaging
• Verf.angabe: Seung-Hyun Kim, Michael Behnes, Michele Natale, Julia Hoffmann, Nadine Reckord, Ursula Hoffmann, Johannes Budjan, Thomas Henzler, Theano Papavassiliu, Martin Borggrefe, Thomas Bertsch, and Ibrahim Akin
• Jahr: 2016
• Fussnoten: Gesehen am 07.02.2019
• Titel Quelle: Enthalten in: Disease markers
• Ort Quelle: New York, NY [u.a.] : Hindawi, 1993
• Jahr Quelle: 2016
• Band/Heft Quelle: 2016(2016) Artikel-Nummer 7402784, 9 Seiten
• ISSN Quelle: 1875-8630
• DOI: doi:10.1155/2016/7402784
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1587359855

Abstract

Background. This study investigates whether serum levels of galectin-3 may reflect impaired mitral annular plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI). Methods. Patients undergoing cMRI during routine clinical care were included prospectively within an all-comers design. Blood samples for biomarker measurements were collected within 24 hours following cMRI. Statistical analyses were performed in all patients and in three subgroups according to MAPSE (MAPSE I: ≥11 mm, MAPSE II: ≥8 mm-<11 mm, and MAPSE III: <8 mm). Patients with right ventricular dysfunction (<50%) were excluded. Results. 84 patients were included in the study. Median LVEF was 59% (IQR 51-64%). Galectin-3 correlated significantly with NT-proBNP (, ). Galectin-3 increased significantly according to the different stages of impaired MAPSE () and was able to discriminate both patients with impaired MAPSE <11 mm (area under the curve (AUC) = 0.645, ) and <8 mm (AUC = 0.733, ). Combining galectin-3 with NT-proBNP improved discrimination of MAPSE <8 mm (AUC 0.803, ). In multivariable logistic regression models galectin-3 was still associated with impaired MAPSE (MAPSE < 11 mm: odds ratio (OR) = 3.53, ; MAPSE < 8 mm: OR = 3.18, ). Conclusions. Galectin-3 reflects MAPSE being assessed by cardiac MRI.